Colin Molloy

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Optical, contact-free assessment of brain tissue stiffness and neurodegeneration.

Optical, contact-free assessment of brain tissue stiffness and neurodegeneration.

Journal: Biomedical optics express

Published: October 28, 2024

M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease.

M1 muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease.

Journal: Science signaling

Published: November 15, 2022

Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease.

Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 04, 2021

Restoring Agonist Function at a Chemogenetically Modified M1 Muscarinic Acetylcholine Receptor.

Restoring Agonist Function at a Chemogenetically Modified M1 Muscarinic Acetylcholine Receptor.

Journal: ACS chemical neuroscience

Published: November 16, 2020

Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice.

Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice.

Journal: Science signaling

Published: August 14, 2020

From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.

From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.

Journal: Cell

Published: June 19, 2020

Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.

Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.

Journal: Nature chemical biology

Published: June 12, 2019

DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo.

DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo.

Journal: ACS pharmacology & translational science

Published: April 30, 2018

Chemogenetics defines receptor-mediated functions of short chain free fatty acids.

Chemogenetics defines receptor-mediated functions of short chain free fatty acids.

Journal: Nature chemical biology

Published: March 14, 2018

Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes.

Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes.

Journal: Molecular pharmacology

Published: January 24, 2018

M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.

M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.

Journal: The Journal of clinical investigation

Published: March 11, 2016

Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice.

Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice.

Journal: Science translational medicine

Published: October 11, 2013

Showing 1-12 of 13

Last Updated: 09/26/2026